Page 2 - Pharmaengine Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PharmaEngine Inc (智擎生技) founder Grace Yeh (葉常菁) has become the Industrial Technology Research Institute’s (ITRI, 工業技術研究院) first female fellow since it started awarding business leaders with fellowships 10 years ago. ITRI chairman Lee Chih-kung (李世光) told the 10th ITRI Laureates award ceremony on Tuesday that Yeh’s induction was significant, because in addition to being the institute’s 50th laureate, she is its first female fellow. Yeh said she was surprised to learn that she was the first woman to be awarded. Taiwan has many outstanding female leaders in...

NANOBIOTIX Announces First Quarter Operational and Financial Updates Expanded clinical data set supporting tumor agnostic potential of NBTXR3 in presentation of first results in rectal cancer at ASCO-GI 2021 Initiated new combination study evaluating NBTXR3 activated by radiation in combination with chemotherapy in esophageal cancer and reported new preclinical data in immunotherapy at AACR RSM 2021, providing further support for radioenhancer NBTXR3 as a therapeutic combination-agnostic that could prime adaptive immune response for local and systemic control New collaboration agreement signe...

NANOBIOTIX and PharmaEngine Mutually Agree to Conclude Collaboration PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘ Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company has reached an agreement with PharmaEngine, Inc. (“PharmaEngine”) to terminate the License and Collaboration agreement that the Company and PharmaEngine entered into in August 2012. As previously...

The agreement provided PharmaEngine exclusive rights to further the development of NBTXR3 in the Asia-Pacific region. Nanobiotix filed a prospectus last year notifying PharmaEngine of a material breach of the terms of the agreement. PharmaEngine denied any breach and asserted certain material breaches of that agreement by Nanobiotix. Pursuant to this termination, Nanobiotix will retain all rights to the development and commercialization of NBTXR3 in the Asia-Pacific region. PharmaEngine will receive payments not exceeding $5 million in total. In the future, PharmaEngine will be entitled to re...

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 4, 2021--Regulatory News: NANOBIOTIX (Euronext : NANO -- NASDAQ: NBTX - the '' Company''), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company has reached an agreement with PharmaEngine, Inc. ('PharmaEngine') to terminate the License and Collaboration agreement that the Company and PharmaEngine entered into in August 2012. As previously disclosed in the Nanobiotix prospectus filed with the U.S. ...